The partnership comes off the back of the success of the 100,000 Genomes Project in December 2018.
News
Novartis, NHS strike ‘innovative’ cardiovascular deal
Novartis’ inclisiran will be studied in UK patients as part of a large-scale NHS clinical trial, which is expected to start later this year.
Zytiga, Ajovy among latest SMC decisions
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Lynparza granted Priority Review in US
The first-in-class PARP inhibitor was also recently approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer.
Elasmogen secures £2m to support next gen biologics
The Scottish company currently has drug libraries of more than 100 billion unique soloMERs.
Eli Lilly set to acquire Dermira, including lebrikizumab
The deal is valued at around $1.1 billion.
ViiV submits fostemsavir MAA to EMA
The application is based on results from the BRIGHTE study, in which the drug showed superiority to placebo.
December NHS stats show wait times ‘worst on record’
The situation is being called “totally unacceptable”, with experts demanding “urgent action.”
New ‘fast-track’ system for tinnitus and hearing loss
Currently there are no registered pharmaceutical treatments for hearing loss or tinnitus.
Economic burden of cancer costs UK £7.6bn a year
A report has found that as many as 53% of people with cancer see their income fall by at least one income bracket.
Bayer, Exscientia to explore AI in drug discovery
The companies will use Exscientia’s Centaur Chemist drug discovery platform in order to discover and optimise the novel drug candidates.
UK scientists secure FDA funding for specialised imaging techniques
The project plans to bring experts in advanced Raman spectroscopy and mass spectrometry imaging together.
Hikma, Arecor set to co-develop new injectable meds
The product will be officially announced prior to launch.
Could Prozac help fight neuroblastoma?
Previous studies have found that people on long-term treatment for psychotic illnesses have lower cancer rates.
Ligelizumab continues to trump Xolair in chronic spontaneous urticaria
The Novartis drug can bind to IgE with an 88-fold higher affinity than Xolair.
